Antibodies against human CSF-1R and uses thereof

Patent metadata

Field	Value
Publication number	US-9499625-B2
Application number	US-201514640183-A
Country	US
Kind code	B2
Filing date	Mar 6, 2015
Priority date	Dec 10, 2009
Publication date	Nov 22, 2016
Grant date	Nov 22, 2016

Abstract

The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

First claim

The invention claimed is:

1. An isolated nucleic acid encoding an antibody binding to human CSF-1R, wherein the antibody comprises a heavy chain variable domain and a light chain variable domain, and wherein:
a) the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:7 and the light chain variable domain comprises the amino acid sequence of SEQ ID NO:8;
b) the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:15 and the light chain variable domain comprises the amino acid sequence of SEQ ID NO:16;
c) the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:75 and the light chain variable domain comprises the amino acid sequence of SEQ ID NO:76;
d) the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:83 and the light chain variable domain comprises the amino acid sequence of SEQ ID NO84;
or a humanized version thereof.

2. An isolated nucleic acid encoding an antibody binding to human CSF-1R, wherein the antibody comprises a heavy chain variable domain and a light chain variable domain, and wherein:
a) the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:23 and the light chain variable domain comprises the amino acid sequence of SEQ ID NO:24,
b) the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:31 and the light chain variable domain comprises the amino acid sequence of SEQ ID NO:32,
c) the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:39 and the light chain variable domain comprises the amino acid sequence of SEQ ID NO:40,
d) the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:47 and the light chain variable domain comprises the amino acid sequence of SEQ ID NO:48, or
e) the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:55 and the light chain variable domain comprises the amino acid sequence of SEQ ID NO:56.

3. An isolated nucleic acid encoding an antibody binding to human CSF-1R, wherein the antibody comprises a heavy chain variable domain and a light chain variable domain, and wherein:
a) the heavy chain variable domain comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO: 1, a CDR2 region comprising the amino acid sequence of SEQ ID NO: 2, and a CDR1 region comprising the amino acid sequence of SEQ ID NO:3, and the light chain variable domain comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO: 4, a CDR2 region comprising the amino acid sequence of SEQ ID NO:5, and a CDR1 region comprising the amino acid sequence of SEQ ID NO:6;
b) the heavy chain variable domain comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO: 9, a CDR2 region comprising the amino acid sequence of SEQ ID NO: 10, and a CDR1 region comprising the amino acid sequence of SEQ ID NO: 11, and the light chain variable domain comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO:12, a CDR2 region comprising the amino acid sequence of SEQ ID NO: 13, and a CDR1 region comprising the amino acid sequence of SEQ ID NO: 14;
c) the heavy chain variable domain comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO: 17, a CDR2 region comprising the amino acid sequence of SEQ ID NO: 18, and a CDR1 region comprising the amino acid sequence of SEQ ID NO:19, and the light chain variable domain comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO: 20, a CDR2 region comprising the amino acid sequence of SEQ ID NO:21, and a CDR1 region comprising the amino acid sequence of SEQ ID NO:22;
d) the heavy chain variable domain comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO: 25, a CDR2 region comprising the amino acid sequence of SEQ ID NO: 26, and a CDR1 region comprising the amino acid sequence of SEQ ID NO: 27, and the light chain variable domain comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO:28, a CDR2 region comprising the amino acid sequence of SEQ ID NO: 29, and a CDR1 region comprising the amino acid sequence of SEQ ID NO: 30;
e) the heavy chain variable domain comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO: 33, a CDR2 region comprising the amino acid sequence of SEQ ID NO: 34, and a CDR1 region comprising the amino acid sequence of SEQ ID NO: 35, and the light chain variable domain comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO:36, a CDR2 region comprising the amino acid sequence of SEQ ID NO: 37, and a CDR1 region comprising the amino acid sequence of SEQ ID NO: 38;
f) the heavy chain variable domain comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO:41, a CDR2 region comprising the amino acid sequence of SEQ ID NO: 42, and a CDR1 region comprising the amino acid sequence of SEQ ID NO:43, and the light chain variable domain comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO: 44, a CDR2 region comprising the amino acid sequence of SEQ ID NO:45, and a CDR1 region comprising the amino acid sequence of SEQ ID NO:46;
g) the heavy chain variable domain comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO: 49, a CDR2 region comprising the amino acid sequence of SEQ ID NO: 50, and a CDR1 region comprising the amino acid sequence of SEQ ID NO: 51, and the light chain variable domain comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO:52, a CDR2 region comprising the amino acid sequence of SEQ ID NO: 53, and a CDR1 region comprising the amino acid sequence of SEQ ID NO: 54;
h) the heavy chain variable domain comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO:69, a CDR2 region comprising the amino acid sequence of SEQ ID NO: 70, and a CDR1 region comprising the amino acid sequence of SEQ ID NO:71, and the light chain variable domain comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO: 72, a CDR2 region comprising the amino acid sequence of SEQ ID NO:73, and a CDR1 region comprising the amino acid sequence of SEQ ID NO:74; or
i) the heavy chain variable domain comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO: 77, a CDR2 region comprising the amino acid sequence of SEQ ID NO: 78, and a CDR1 region comprising the amino acid sequence of SEQ ID NO: 79, and the light chain variable domain comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO:80, a CDR2 region comprising the amino acid sequence of SEQ ID NO: 81, and a CDR1 region comprising the amino acid sequence of SEQ ID NO: 82.

4. The isolated nucleic acid of claim 3 , wherein the antibody is of human IgGlsubclass or is of human IgG4 subclass.

5. The isolated nucleic acid of claim 3 , wherein the antibody is a chimeric, single chain, multispecific, or humanized antibody.

6. The isolated nucleic acid of claim 3 , wherein the antibody is an antigen binding fragment.

7. An expression vector comprising the nucleic acid of claim 3 for the expression of the antibody in a prokaryotic or eukaryotic host cell.

8. A prokaryotic or eukaryotic host cell comprising the vector of claim 7 .

9. A method for the production of a recombinant antibody, the method comprising expressing the nucleic acid of claim 3 in a prokaryotic or eukaryotic host cell and recovering the antibody from said cell or cell culture supernatant.

10. The isolated nucleic acid of claim 1 , wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:7 and the light chain variable domain comprises the amino acid sequence of SEQ ID NO:8.

11. The isolated nucleic acid of claim 1 , wherein the heavy chain variable domain co

Assignees

• Hoffmann La Roche

Inventors

• Dimoudis Nikolaos
• Fertig Georg
• Fidler Alexander
• Kaluza Klaus
• Thomas Marlene
• Ries Carola
• Seeber Stefan
• Lanzendoerfer Martin

Classifications

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P35/04

  specific for metastasis · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P19/10

  for osteoporosis · CPC title